



BISTAIRS

Challenges to the development of guidelines and recommendations where the evidence is low

Dr Amy O'Donnell

Institute of Health and Society

Newcastle University


www.bistairs.eu

This action was funded from the European Commission
Public Health Programme (2008–2013)

Going from evidence to guidelines and recommendations


Four key factors :-

1. Quality of evidence
2. Benefits and harms
3. Values and preferences
4. Costs (resource allocation)



But we also need to consider: prevalence of the health problem; issues of equity; acceptability; feasibility

Complex interventions: the evidence development process




www.mrc.ac.uk/complexinterventionsguidance



ASBI in medical settings

Primary health care



ASBI outside medical settings

Workplace

- Some (inconclusive) effectiveness data
- Some (inconclusive) implementation data
- No demonstration data


Social services

- Limited (inconclusive) effectiveness data
- No useful implementation data
- No demonstration data

What next? Screen, intervene, or...?




More research is needed?



Other factors to consider

PROBLEM	<ul style="list-style-type: none">• Is the problem a priority?
	<ul style="list-style-type: none">• Are a large number of people affected?
BENEFITS & HARMS	<ul style="list-style-type: none">• Are the desirable anticipated effects large?
	<ul style="list-style-type: none">• Are the undesirable anticipated effects small?
	<ul style="list-style-type: none">• What Is the overall certainty of this evidence?
VALUES	<ul style="list-style-type: none">• How certain is the relative importance of the desirable and undesirable outcomes?
	<ul style="list-style-type: none">• Are the desirable effects large relative to undesirable effects?
RESOURCE USE	<ul style="list-style-type: none">• Are the resources required small?
	<ul style="list-style-type: none">• Is the incremental cost small relative to the net benefits?
EQUITY	<ul style="list-style-type: none">• What would be the impact on health inequities?
ACCEPTABILITY	<ul style="list-style-type: none">• Is the option acceptable to key stakeholders?
FEASIBILITY	<ul style="list-style-type: none">• Is the option feasible to implement?

Discussion points



- Are we starting from scratch?
- Is there anything we can reasonably take from the PHC evidence base to accelerate implementation?